Please login to the form below

Not currently logged in
Email:
Password:

Huntingdon's disease

This page shows the latest Huntingdon's disease news and features for those working in and with pharma, biotech and healthcare.

Ionis and Roche gain PRIME status for Huntingdons disease candidate

Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

More good news for Ionis after first drug approval. Ionis and Roche’s pipeline drug for Huntingdon’s disease has been granted special ‘PRIME’ status by the European Medicines Agency (EMA). ... s disease to regulatory approval faster.

Latest news

  • EMA hands UniQure orphan status first in Huntington's EMA hands UniQure orphan status first in Huntington's

    Its Huntington’s disease candidate, currently known as AMT-130, becomes the first investigational AAV-gene therapy in this disease area to receive the status. ... UniQure’s candidate fit the bill, not least because there are no currently approved

  • Roche signs Parkinson's deal with Prothena Roche signs Parkinson's deal with Prothena

    Antibody development agreement is worth up to $600m. Roche has upped its efforts in Parkinson's disease by agreeing to research new antibodies with the US biotech Prothena. ... This technology was also a key aspect of a recent deal with Isis to tackle

  • Roche and Isis in $392m deal to research drugs for brain disorder Roche and Isis in $392m deal to research drugs for brain disorder

    The unmet medical need for Huntingdon's disease is compounded by its severity,  with patients enduring progressive loss of both mental faculties and physical control. ... foundation exclusively dedicated to the development of therapies that slow the

  • Bouncing back

    The deal should speed up new treatments for Huntingdon's disease, Parkinson's disease and for strokes. ... attention to incidents of vision loss among patients taking GSK's Levitra, Pfizer's Viagra and Lilly's Cialis.

  • Malcolm's Market Eye: 7 to 13 July 2007

    The market for ReNeuron's treatment is large with some 12m stroke survivors in Japan, the US and the EU, with nearly one third needing continual nursing care. ... ReNeuron is also focusing on inherited Huntingdon's disease and type 1 diabetes needing

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics